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Abstract 
Objective: EEG power in the delta, theta and beta1 bands has been shown to be positively 
correlated with negative symptoms in first episode psychotic patients. The present study 
investigates this correlation in an “at risk mental state for psychosis” (ARMS) with the aim to 
improve prediction of transition to psychosis.  
Methods: Thirteen ARMS patients with later transition to psychosis (ARMS-T) and fifteen 
without (follow-up period of at least 4 years) (ARMS-NT) were investigated using spectral 
resting EEG data (of 8 electrodes over the fronto-central scalp area placed according to the 10 
– 20 system) and summary score of the Scale for the Assessment of Negative Symptoms 
(SANS).  
Linear regressions were used to evaluate the correlation of SANS and EEG power in seven 
bands (delta, theta, alpha1, alpha2, beta1, beta2, beta3) in both ARMS groups and logistic 
regressions were used to predict transition to psychosis. Potentially confounding factors were 
controlled. 
Results: ARMS-T and ARMS-NT showed differential correlations of EEG power and SANS 
in delta, theta, and beta1 bands (p <0.05): ARMS-T showed positive and ARMS-NT negative 
correlations. Logistic regressions showed that neither SANS score nor EEG spectral power 
alone predicted transition to psychosis. However, SANS score in combination with power in 
the delta, theta, beta1, and beta2 bands, respectively, predicted transition significantly (p 
<0.03).  
Limitations: The number of subjects is relatively small. The difference in age of both study 
groups might be considered as a further limitation even though age had no effect on the 
results according to confounder analysis.  
Conclusions: ARMS-T and ARMS-NT show differential correlations of SANS summary 
score and EEG power in delta, theta, and beta bands. Prediction of transition to psychosis is 
possible using combined information from a negative symptom scale and EEG spectral data.  
Gelöscht: Introduction
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Introduction 
Ultra high risk studies aim at improving the early detection of psychosis in order to provide 
earlier and more efficient treatment to patients suffering from psychosis.1-2 Predominant 
criteria utilized to date are attenuated (sub-threshold) psychotic symptoms of brief limited 
psychotic episodes, genetic risk, and social decline.3 However, not all patients identified as 
being in an “at risk mental state for psychosis” (ARMS) by these criteria develop psychosis. 
The differentiation between ARMS patients who will make the transition to psychosis 
(ARMS-T) and ARMS patients who will not develop the disease (ARMS-NT) is of crucial 
importance. Recently reported transition-to-psychosis rates from our group were 34%4 and 
ranged from 9% to 54% in other high risk studies (see review by Olsen et al.)5. Other recent 
studies suggest transition rates of about 15%.6-7 Thus, current criteria result in many ‘false 
positives’, which puts unnecessary burden on patients. Supplementary to the criteria of Yung 
et al.3 other risk factors have been detected that can potentially improve the identification of 
ARMS-T patients.  
• ARMS-T patients are more severely impaired in certain neuropsychological domains 
compared to ARMS-NT patients and can be discriminated based on cognitive 
performances.8 For example, in a recent study of Riecher-Rössler et al.4 
neuropsychological data were combined with psychopathological ratings (i.e., Brief 
Psychiatric Rating Scale, BPRS)9 and Scale for the Assessment of Negative 
Symptoms (SANS)10 to enhance prediction of transition to psychosis. 
• Neuroimaging studies (for review Wood et al.)11 detected structural changes in ARMS 
patients using structural magnetic resonance imaging.12 Koutsouleris et al.13 were able 
to classify ARMS-T patients with an accuracy of 88% using a multivariate whole-
brain technique.  
• Evoked potential studies have been conducted in ARMS patients (e.g.14-16). However, 
so far only Brockhaus-Dumke et al.17 compared ARMS-T with ARMS-NT. Their 
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results indicate that N100 suppression evaluated in a double click paradigm is 
significantly reduced in ARMS-T (p < 0.05), first episode (FE, p < 0.001), as well as 
chronic patients (p <0.001) compared to healthy controls but not ARMS-NT (p = 
0.052). However, ARMS-T and ARMS-NT did not differ on any of the studied 
parameters.  
• Moreover, conventionally (non quantitatively) analyzed resting EEG was shown to 
increase the specificity of prediction of transition to psychosis in ARMS from 59% to 
73%.18  
The present study tests the hypothesis that a combination of negative symptoms and spectral 
power of resting EEG increases predictive accuracy of transition to psychosis in ARMS 
patients. This hypothesis originates from the observation that negative symptoms and 
quantitative EEG (qEEG) spectral power are correlated in different types of medicated and 
unmedicated schizophrenic patients.19-27 Moreover, a recent study by our group28 showed that 
negative symptoms are positively correlated with qEEG absolute power in delta (0.5-4 Hz), 
theta (4-8 Hz) and beta1 (12-15 Hz) bands in the first episode (FE) of schizophrenia in 
neuroleptic-naïve patients. Presence of these correlations in neuroleptic naïve FE patients is a 
first requirement for the combination of negative symptoms with qEEG findings in ARMS 
patients to be a valid predictor for transition to psychosis. We expected to find correlations in 
the group of ARMS-T patients similar to those found in FE patients. A further requirement for 
the prediction of transition is absence of these correlations in ARMS-NT patients.  
Thus, the objectives of the current study are to examine 1) whether the correlation of negative 
symptoms and EEG spectral power in ARMS-T patients is similar to that observed in the 
previously analyzed FE patients, but absent or different in ARMS-NT patients, and 2) 
whether it is possible to improve prediction of transition to psychosis in ARMS patients based 
on an increase of power in delta, theta, and beta1 frequency bands in combination with a 
negative symptom score (SANS).  
Gelöscht:  
Gelöscht:  
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Methods 
 
Subjects 
 
Data from 13 ARMS-T and 15 ARMS-NT patients from the FEPSY (Early Detection of 
Psychosis) Clinic at the University Psychiatric Outpatient Department, Basel, Switzerland 
were analyzed. Baseline data including BPRS, SANS and EEG were collected at patients’ 
first intake into clinic. Patients were then regularly followed-up. Criteria for ARMS and 
transition to psychosis were defined according to Yung et al.3 and are shown in Table 1. The 
detailed screening process has been described elsewhere.4, 29 
 
--- Insert Table 1 about here --- 
 
Exclusion criteria were age younger than 18 years, insufficient knowledge of German, IQ 
<70, previous episode of schizophrenic psychosis (treated with major tranquillizers for >3 
weeks), psychosis clearly due to organic reasons or substance abuse, or psychotic symptoms 
within a clearly diagnosed depression or borderline personality disorder. 
After complete description of the study to the subjects, written informed consent was obtained 
from all participants. The study was approved by the local ethics committee 
(Ethikkommission beider Basel, EKBB). A further condition for ARMS-NT patients was a 
follow-up period of at least four years. Four patients were on low dose neuroleptics 
(chloprothixen) prescribed for sedation, six patients were treated with antidepressive drugs 
(escitalopram, citalopram, paroxetine, sertralin, fluoxetin, venlafaxin) and three patients were 
on benzodiazepines (lorazepam, zolpidem). The patients’ mean age was 25.7 (SD 7.6), 18 
subjects were male and 10 were female.     
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Psychopathological ratings 
 
Patients were rated at study entry (baseline) with the Scale for the Assessment of Negative 
Symptoms (SANS)10 which consists of five subscales that evaluate aspects of negative 
symptoms (alogia, affective blunting, avolition-apathy, anhedonia-asociality, and attentional 
impairment). We calculated SANS summary score as described by Andreasen.30 Mean SANS 
summary score was 8.4 (SD 5.5, range 0-19). The variable was normally distributed.  
 
EEG data acquisition 
 
Only patients with a digitally recorded EEG at study entry (“baseline”) were included. 
Routine EEG recordings of about 20 min duration were performed in a quiet room with 
closed eyes. Patients were instructed by the technicians to open eyes about every third minute 
for a period of five to six seconds. Additional open eyes segments were required if the patient 
showed signs of sleepiness.  
EEG data were digitally recorded using 21 gold cup electrodes placed according to the 
international 10/20 system. Impedances were kept below 5 kΩ. Amplifiers were calibrated 
using a 50 µV square pulse. Sampling frequency was 250 Hz. All channels were referenced to 
linked ears. EEGs were recorded with Alliance Works for Windows NTTM (Nicolet 
Biomedical Inc., Madison, Wisconsin). Raw EEG data were converted to European Data 
Format with Nicolet Data Converter (Nicolet Biomedical Inc., Madison, Wisconsin). Data 
were then read into Brain Vision Analyzer© software (BVA; Brain Products GmbH, Munich, 
Germany). We selected 19 electrodes (Fp1, Fp2, F3, F4, C3, C4, P3, P4, O1, O2, F7, F8, T3, 
T4, T5, T6, Fz, Cz and Pz), recalculated the reference to average and set the high- and low 
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pass (Butterworth) filters to 0.5–120 Hz. We then removed eyes open sequences that had been 
marked by the technicians during the recording with the tool “Segmentation” of BVA.  
 
Artefact rejection 
To ensure high validity of the analysis Boutros et al.31 recommend a minimum of 25 artefact 
free segments of 2 seconds duration (see also Lund et al.).32 To conserve a maximum of EEG 
recording we used a semi-automatic standard operating procedure (SOP) to remove artefacts. 
The procedure consisted of three steps: 1) Continuous data containing obvious artefacts (e.g., 
electrode artefacts), except for those caused by eye movements, were manually deleted over 
all electrodes and remaining segments were juxtaposed. 2) In order to remove well defined 
sources of artefact, an independent component analysis (ICA) was performed with BVA. 
Once the independent time courses of different brain and artefact sources were extracted from 
the data, corrected EEG signals were computed by eliminating the contributions of the 
artefact sources. The ICA has been demonstrated to reliably isolate artefacts due to horizontal 
and vertical eye movements, heart electrical interference, and to some extent muscle or line 
noise.33 3) In a last step, the already corrected EEG was visually inspected by an experienced 
neurophysiologist who was blind to the patient’s symptoms and diagnosis. He removed 
further artefacts not readily removed in steps 1 and 2 from the EEG recording, including 
muscle, movement and electrode artefacts. Patients with EEGs containing deeper sleep than 
stage A of Loomis et al.34 and with EEGs that showed EEG-identifiable pathologies (e.g., 
generalized epilepsy) were excluded from further analyses. After artefact removal, EEG 
recordings were divided into segments of two seconds. The remaining EEG recordings had a 
minimum length of 68 two-second-segments and an average length of 204.5 sec (SD=122).   
 
Analysis and statistics 
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EEG power for all electrode sites was calculated using Fast Fourier Transform (FFT) 
(Hanning Window, 20% taper length, 0.5 Hz bins from 0.5 to 30 Hz) implemented in BVA. 
Data were exported into R-Software35 for statistical analysis. The FFT output data over the 
0.5 Hz bins were combined to delta (0.5–4 Hz), theta (4–8 Hz), alpha1 (8–10 Hz), alpha2 
(10–12 Hz), beta1 (12–15 Hz), beta2 (15–25 Hz) and beta3 (25–30 Hz) bands by calculating 
the mean of the corresponding 0.5 Hz frequency bins. Analyses were performed a-priori on 
average power of the 8 electrode sites used in our previous study,28 roughly covering the 
fronto-central half of the scalp (Fp1, F3, C3, Fz, Cz, Fp2, F4, C4). Other locations were not 
analyzed to minimize type I error. All EEG variables were transformed by natural logarithm 
to achieve normal distribution.  
 
Correlation of EEG spectral power with SANS scores in ARMS patients 
 
We performed one general linear regression per EEG band using absolute spectral power as 
dependent variable. Negative symptom score as well as group (ARMS-T vs. ARMS-NT) and 
the interaction term of group and negative symptom score were independent variables. We 
controlled for potential confounders (age, gender, use of benzodiazepines, use of 
antidepressants, use of low-dose neuroleptics, use of cannabis, and day time of EEG 
recording) by doing sensitivity analysis, i.e., we inserted the potentially confounding factors 
one by one into the regression models and checked whether the additional factor had relevant 
influence on the reported results.  
To better illustrate the correlations of power and SANS for each group separately estimates 
and 95% confidence intervals (CI) were derived from mathematically equivalent stratified 
linear models with group-specific slopes of the negative symptoms variable (i.e., the 
respective group-specific terms were obtained by multiplying the original negative symptoms 
variable with the respective group indicator variable).  
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To control for interindividual variability in EEG absolute power, we additionally calculated 
mixed effect models.36 For every band, power with a resolution of 0.5 Hz was used as 
dependent variable. Group and SANS score were used as fixed effects as in the general linear 
regression models. Intercept was used as random effect.  
 
Prediction of transition to psychosis 
 
To predict transition to psychosis using EEG power and SANS summary score collected at 
baseline, logistic regression models were calculated. ARMS status (T vs. NT) was used as 
dependent variable. Negative symptoms and EEG power (as well as the interaction of both 
variables) were used as independent variables. Finally, optimal cut-off scores for determining 
sensitivity, specificity, and prediction accuracy were calculated for the logistic regression 
models. 
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Results 
 
Sample description 
 
Table 2 summarizes characteristics of the studied groups. While ARMS-T and ARMS-NT 
differed in age (p = 0.03) and while EEGs of both groups were recorded at different times of 
day (p = 0.02), no statistical difference could be found in terms of gender, medication, use of 
cannabis, intensity of negative symptoms, BPRS score and absolute power in different bands.  
 
--- Insert Table 2 about here --- 
 
Correlation of EEG spectral power with SANS scores in ARMS patients 
 
Table 3 shows results of linear regression models describing the correlation between power in 
seven frequency bands and negative symptoms (SANS summary score) for both groups 
(ARMS-T vs. ARMS-NT). 
 
--- Insert Table 3 about here --- 
 
The significant interaction effect between negative symptoms and group indicates that the 
correlation of negative symptoms and power is differential in ARMS-T and ARMS-NT in the 
delta (p = 0.016), theta (p = 0.033), and beta1 (p = 0.036) bands.  
 In ARMS-NT power decreases in these bands with stronger negative symptoms (see 
estimates and CI in Table 3). In contrast, power of the ARMS-T group increases with stronger 
negative symptoms in the same bands (see Table 3 and Figure 1). 
 
Gelöscht: One patient was excluded due 
to sleepiness during EEG recording, one 
due to persistent electrode and movement 
artifacts. 
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 --- Insert Figure 1 about here --- 
 
 
Influence of additional variables 
 
According to sensitivity analysis, none of the potentially confounding factors (including age 
and daytime of EEG recording) had significant effects on the discussed bands nor did any of 
them affect the reported results with the exception of intake of benzodiazepines which had a 
significant effect in the beta2 (p = 0.029) and beta3 (p = 0.006) bands. We redid the analysis 
excluding patients on benzodiazepines: The estimates of regression analysis did not relevantly 
change. A table with results of this sub-analysis can be seen in the supplemental material of 
the paper. 
 
Further analyses  
 
The results of the random effect procedure were similar to those of the linear regression 
models and can be seen in the supplemental material of the paper.  
 
Comparison with first episode patients 
 
In Figure 2, Spearman rank order correlation coefficients of the current analysis with ARMS 
patients are displayed together with those of FE patients described in our previous study.28 
The figure shows that FE and ARMS-T patients exhibit a remarkably similar correlation 
pattern across the entire EEG frequency range. In contrast, the correlation coefficients of 
ARMS-NT patients are dissimilar and largely in the negative range.  
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--- Insert Figure 2 about here --- 
 
Prediction of transition to psychosis 
 
Neither SANS nor EEG power scores alone were predictive for transition to psychosis. 
Results of logistic regression models combining negative symptoms and power are presented 
in Table 4. The models for the delta, theta, beta1 and beta2 bands had statistically significant 
predictive power (p < 0.05). Within these models the interaction terms (of power and negative 
symptoms) were significant (p < 0.05) as well as the main effects of negative symptoms in 
models theta, beta1 and beta2.      
 
--- Insert Table 4 about here --- 
 
Table 4 also lists Nagelkerke’s R2 index, optimal probability cut-off scores, the percentage of 
correctly classified patients, sensitivity and specificity as well as positive and negative 
predictive values. Best prediction of transition to psychosis was reached with the model 
combining negative symptoms with power in the theta band with 89% correct classifications. 
Also the models combing SANS summary score and power in delta, beta1 and beta2 bands 
showed high predictive accuracy (PPC > 0.80).  
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Discussion 
 
The first objective was to investigate whether the positive correlations of EEG power in the 
delta, theta, and beta1 bands with negative symptoms, previously observed in FE patients,28 
are already present before the clinical outbreak (in ARMS-T patients). Direction and degree 
of these correlations in ARMS-T patients are almost equivalent to those observed in FE 
patients (see Table 3), although confidence intervals were not clearly in the positive range, 
probably due to small sample size (N = 13). In ARMS-NT, in contrast, correlations of power 
in these bands with negative symptoms were clearly negative. Thus, the correlation pattern of 
ARMS-NT patients was almost a mirror image to that of ARMS-T and FE (see Figure 2). 
Interaction terms of linear regression analyses indicated that correlations of SANS summary 
score and power in delta, theta, and beta1 bands differed significantly between ARMS-T and 
ARMS-NT. Therefore, the first hypothesis of the study, stating that the relationship of 
negative symptoms and EEG spectral power in ARMS-T patients is similar to that observed in 
FE, but different in ARMS-NT patients, is largely confirmed.  
The second objective was to assess the accuracy of models comprising SANS and qEEG data 
for prediction of transition of ARMS patients to psychosis. Logistic regression models 
showed significant predictions for delta, theta, beta1, and surprisingly, for the beta2 band (see 
Table 4). The models classified transition to psychosis in ARMS patients with an accuracy of 
over 80%. Therefore, the second hypothesis, stating that it is possible to improve prediction of 
transition to psychosis in ARMS patients based on power in delta, theta, and beta1 bands in 
combination with the SANS score, is confirmed. The study suggests that EEG spectral 
analysis in combination with SANS score might be helpful in predicting transition or non-
transition to psychosis in ARMS.  
Other applications are conceivable: Currently efforts are made to increasingly base future 
classification systems of psychoses on biological data.37 The positive correlations of EEG 
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power and negative symptoms have been observed in chronic stages of schizophrenia,20, 23, 25, 
27
 in FE patients28 and with the present study also in the prodromal phase of psychosis 
(ARMS-T) while the same correlations showed sign reversal in a non-psychotic control group 
(ARMS-NT). QEEG data might, thus, represent an endophenotype38 associated with 
behavioral symptoms and could, therefore, be helpful in the differential diagnosis of disorders 
with negative symptoms.  
The associating of higher EEG power in low frequency bands with stronger negative 
symptoms in schizophrenic patients might be due to a lack of activity in non-motor cortico-
basalganglionic-thalamo-cortical circuits as proposed for negative symptom like signs and 
EEG alterations in Parkinson’s disease.39-41 Speculation about the mechanism underlying the 
sign reversed correlation in the control group is, however, difficult at this stage.  
The current study represents an initial foray into a vital clinical field. Up to now, the question 
of the specificity of the phenomenon has not been sufficiently investigated and, therefore, 
studies including different pathological control populations and, additionally, studies with 
repeated assessment of qEEG in high-risk populations, including patients under the age of 18, 
to address the question whether EEG alterations represent a state or a trait marker are 
warranted. Although results are probably not affected by any confounding factors as shown 
by carefully conducted sensitivity analyses, future studies should make efforts to investigate 
these phenomena in samples that are comparable in age, which could not be done in the 
present study. 
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Table 1: Criteria for ARMS and transition to psychosis 
  
 
Note: BPRS = Brief Psychiatric Rating Scale (Lukoff, 1986) 
 
  Clinical signs 
At Risk 
Mental State 
(ARMS) 
A) “Attenuated” psychotic symptoms: psychotic symptoms below the 
transition cut-off (BPRS scales: ratings of hallucinations at 2-3, unusual 
thought content 3-4, or suspiciousness 3-4) at least several times per 
week persisting for >1 week; OR  
B) Brief Limited Intermittent Psychotic Symptoms (BLIPS): psychotic 
symptoms over the transition cut-off (BPRS scales: hallucinations ≥4, 
unusual thought content ≥5, suspiciousness ≥5, conceptual 
disorganization ≥5), but each symptom lasting <1 week before 
resolving spontaneously 
C) Genetic risk category: first or second degree relative with psychotic 
disorder 
        and at least two further risk factors according to the screening 
instrument. 
D) Precondition for all categories: criteria of transition to psychosis remain 
unfulfilled. 
Transition to 
Psychosis 
 
At least one of the following symptoms: 
• suspiciousness (BPRS ≥5): subject says others are maliciously talking 
about him/her, have negative intentions or may induce harm (incidents 
more than once a week OR partly delusional conviction). 
• unusual thought content (BPRS ≥5): full delusion(s) with some 
preoccupation OR some areas of functioning disrupted (not only ideas 
of reference/ persecution, unusual beliefs or bizarre ideas without fixed 
delusional conviction) 
• hallucinations (BPRS ≥4): occasional hallucinations OR visual 
illusions >2 week or with functional impairment (not only hearing of 
own name, non-verbal acoustic or formless visual 
hallucinations/illusions). 
• conceptual disorganization (BPRS ≥5): speech difficult to understand 
due to circumstantiality, tangentiality, neologisms, blockings or topic 
shifts (most of the time OR three to five instances of incoherent 
phrases). 
• Symptoms at least several times a week and change in mental state 
lasting for more than one week.  
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Table 2: Demographic and clinical characteristics of ARMS-T vs. ARMS-NT patient 
groups at baseline 
 ARMS-NT ARMS-T Inferential statistic 
N 15 13  
Gender (male) 66.6 % 61.5 % *p = 1 
Age, mean (SD) years 23.1 (6.9) 28.7 (7.5) †W = 50; p = 0.003 
High dose neuroleptics 0 % 0 % Not available 
Low dose neuroleptics  13.3 % 15.4 % *p = 1 
Antidepressants 20 % 23.1% *p = 1 
Benzodiazepines 6.7 % 15.4 % *p = 0.58 
Mood stabilizer 0 % 7.7 % *p = 0.46 
Cannabis use    
no 10 8  
less than monthly 0 0  
monthly 1 0 
‡
χ2 (df=3) = 0.13;  
p = 0.73 
weekly 2 3  
daily 2 2  
Day time of EEG 
recording (SD) 10.2 (2.1) 13 (3) 
‡W = 49; p = 0.002 
SANS global score,  
mean (SD) 7.6 (5.7) 9.4 (5.3) 
§t (df=25.8) = -0.86;  
p = 0.40 
BPRS summary score, 
mean (SD) 38.6 (10.1) 41.6 (9.1) 
§t (df=25.9) = -0.76;  
p = 0.46 
EEG power    
delta (0.5 - 4 Hz, log), 
mean (SD) 0.13 (0.47) 0.1 (0.38) 
§t (df=25.9) = 0.17;  
p = 0.86 
theta (4 - 8 Hz, log), 
mean (SD) -0.91 (0.6) -0.78 (0.72) 
§t (df=23.6) = -0.50;  
p = 0.62 
alpha1 (8 - 10  Hz, log), 
mean (SD) -0.47 (0.99) 0.19 (1.16) 
§t (df=23.8) = -1.60;  
p = 0.12 
alpha2 (10 - 12 Hz, log), 
mean (SD) 0.19 (1.05) -0.09 (0.96) 
§t (df=25.9) = -0.73;  
p = 0.47 
beta1 (12 - 15 Hz, log), 
mean (SD) -1.33 (0.77) -0.128 (0.68) 
§t (df=26) = -0.19;  
p = 0.85 
beta2 (15 - 25 Hz, log), 
mean (SD) -2.01 (0.65) -1.86 (0.68) 
§t (df=25.0) = -0.83;  
p = 0.41 
beta 3 (25 - 30 Hz, log), 
mean (SD) -2.73 (0.63) -2.41 (0.82) 
§t (df=22.5) = -1.2;  
p = 0.25 
 
*Fisher’s exact test for Count Data; †Wilcoxon rank sum test with continuity correction; 
‡Pearson's Chi-squared Test for Count Data; §Student's t-Test. “Log” indicates that variable 
was transformed by natural logarithm. 
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Table 3: Results of linear regression analysis 
 
qEEG spectral band 
Estimate 
[b] 
[CI 95%] 
p-value of 
interaction 
Delta (Overall Model)      
Negative symptoms of ARMS-T b = 0.12 [-0.10, 0.35] 
0.016 
Negative symptoms of ARMS-NT b = -0.26 [-0.45, -0.07] 
Theta (Overall Model)      
Negative symptoms of ARMS-T b = 0.24 [-0.13, 0.60] 
0.033 
Negative symptoms of ARMS-NT b = -0.31 [-0.62, 0.00] 
Alpha1 (Overall Model)      
Negative symptoms of ARMS-T b = 0.13 [-0.54, 0.80] 
0.331 
Negative symptoms of ARMS-NT b = -0.32 [-0.90, 0.25] 
Alpha2 (Overall Model)      
Negative symptoms of ARMS-T b = 0.14 [-0.47, 0.75] 
0.323 
Negative symptoms of ARMS-NT b = -0.24 [-0.76, 0.28] 
Beta1 (Overall Model)      
Negative symptoms of ARMS-T b = 0.20 [-0.20, 0.60] 
0.036 
Negative symptoms of ARMS-NT b = -0.39 [-0.73, -0.05] 
Beta2 (Overall Model)      
Negative symptoms of ARMS-T b = 0.09 [-0.30, 0.48] 
0.175 
Negative symptoms of ARMS-NT b = -0.27 [-0.61, 0.06] 
Beta3 (Overall Model)      
Negative symptoms of ARMS-T b = -0.07 [-0.52, 0.38] 
0.933 Negative symptoms of ARMS-NT b = -0.06 [-0.45, 0.32] 
 
Note: Table 3 shows group specific estimates and confidence intervals of the correlation of EEG power and 
SANS summary score in seven frequency bands derived from stratified linear models. P-value of interactions 
of negative symptoms with group indicates if the correlation in the respective band behaves differently 
according to group (ARMS-T vs. ARMS-NT).  
 
Kommentar [p1]: Liesse sich b= nicht 
unter Estimate einfügen und so eine Spalte 
'sparen'? 
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Table 4: Results of logistic regression analysis 
Variables Estimate Std. Error Statistic p-value R2 Cut- 
off PCC 
Sens PPV 
Spec NPV 
Model Delta 
   
  0.024 
0.38 0.40 0.82 0.92 0.73 
0.75 
0.92 
Delta absolute power b = -0.51 1.29 z = -0.39 0.694 
Negative symptoms b = -0.09 0.54 z = -0.17 0.867 
Interaction (Power*Negative Symptoms) b = 4.08 1.81 z = 2.26 0.024 
Model Theta 
     0.001 
0.58 0.35 0.89 0.92 0.87 
0.86 
0.93 
Theta absolute power b = 0.31 1.03 z = 0.30 0.761 
Negative symptoms b = 6.17 2.47 z = 2.50 0.012 
Interaction (Power*Negative Symptoms) b = 5.96 2.48 z = 2.41 0.016 
Model Alpha1 
     0.097 
0.27 0.61 0.71 0.46 0.93 
0.86 
0.67 
Alpha1 absolute power b = 0.62 0.46 z = 1.36 0.174 
Negative Symptoms b = 0.95 0.59 z = 1.61 0.108 
Interaction (Power*Negative Symptoms) b = 0.90 0.64 z = 1.41 0.158 
Model Alpha2 
     0.556 
0.01 0.50 0.71 0.69 0.73 
 
0.69 
0.73 
 
Alpha2 absolute power b = -0.18 0.43 z = -0.41 0.680 
Negative Symptoms b = 0.34 0.40 z = 0.84 0.399 
Interaction (Power*Negative Symptoms) b = 0.38 0.42 z = 0.89 0.372 
Model Beta1 
     0.041 
0.34 0.44 0.82 0.92 0.73 
0.75 
0.92 
Beta1 absolute power b = 0.79 0.74 z = 1.07 0.283 
Negative Symptoms b = 3.13 1.34 z = 2.34 0.019 
Interaction (Power*Negative Symptoms) b = 1.82 0.79 z = 2.32 0.021 
Model Beta2 
     0.032 
0.36 0.43 0.82 0.85 0.80 
0.79 
0.86 
Beta2 absolute power b = 0.51 0.77 z = 0.66 0.508 
Negative Symptoms b = 6.81 3.09 z = 0.20 0.028 
Interaction (Power*Negative Symptoms) b = 2.88 1.33 z = 0.17 0.030 
Model Beta3 
     0.457 
0.12 0.45 0.75 0.77 0.73 
0.71 
0.79 
Beta3 absolute power b = 0.84 0.71 z = 1.19 0.235 
Negative Symptoms b = 0.00 2.64 z = 0.00 0.999 
Interaction (Power*Negative Symptoms) b = -0.15 0.97 z = -0.15 0.879 
 
Note: Table 4 shows results of logistic regression models predicting transition to psychosis in ARMS patients based 
on the combination of negative symptom score and power scores in seven frequency bands. The last columns of the 
table show Nagelkerke’s R2 index, the optimal cut-off values, percentage of correctly classified individuals (PCC), 
sensitivity and specificity as well as positive predictive values (PPV) and negative predictive values (NPV) for the 
logistic regressions.  
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Figure 1 Scatterplots of negative symptoms (SANS summary scores, z-transformed) and 
EEG power in seven frequency bands for ARMS-T (∆) and ARMS-NT (x) patients 
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Figure 2 Correlation coefficients of EEG spectral power at different frequencies with SANS 
summary scores for ARMS-T and ARMS-NT patients. Greek letters represent the bands as 
they were defined for the linear regression analysis. Results of first episode (FE) patients28 
are displayed for comparison. 59 % of FE patients were male, mean age was 32 years (9.8 
SD), 3 were on antidepressants, 4 on benzodiazepines, 8 used cannabis. Mean SANS 
summary score in FE patients was 7.4 (4.6 SD).    
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